Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: the FFCD-PRODIGE 37 randomized phase II study (FIRGEMAX)
ANNÉE
2020
AUTEURS
Rinaldi Y, Pointet AL, Khemissa Akouz F, Le Malicot K, Wahiba B, Louafi S, Gratet A, Miglianico L, Laharie H, Bouhier Leporrier K, Thirot Bidault A, Texereau P, Coriat R, Terrebonne E, Gouttebel MC, Malka D, Bachet JB, Lepage C, Taieb J
CONGRÈS/REVUE
Eur J Cancer
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES